Wilson, A.L.; Moffitt, L.R.; Wilson, K.L.; Bilandzic, M.; Wright, M.D.; Gorrell, M.D.; Oehler, M.K.; Plebanski, M.; Stephens, A.N.
DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model. Cancers 2021, 13, 487.
https://doi.org/10.3390/cancers13030487
AMA Style
Wilson AL, Moffitt LR, Wilson KL, Bilandzic M, Wright MD, Gorrell MD, Oehler MK, Plebanski M, Stephens AN.
DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model. Cancers. 2021; 13(3):487.
https://doi.org/10.3390/cancers13030487
Chicago/Turabian Style
Wilson, Amy L., Laura R. Moffitt, Kirsty L. Wilson, Maree Bilandzic, Mark D. Wright, Mark D. Gorrell, Martin K. Oehler, Magdalena Plebanski, and Andrew N. Stephens.
2021. "DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model" Cancers 13, no. 3: 487.
https://doi.org/10.3390/cancers13030487
APA Style
Wilson, A. L., Moffitt, L. R., Wilson, K. L., Bilandzic, M., Wright, M. D., Gorrell, M. D., Oehler, M. K., Plebanski, M., & Stephens, A. N.
(2021). DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model. Cancers, 13(3), 487.
https://doi.org/10.3390/cancers13030487